Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years
Stopped Pfizer has made an internal business decision to terminate the B1791094 study. This decision was not due to safety concerns or requests from any regulatory authorities.
Conditions
Interventions
- DRUG: Full dose Pantoprazole plus matching placebo
- DRUG: Half Dose Pantoprazole plus matching placebo
Sponsor
Pfizer